FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4300900655> ?p ?o ?g. }

• W4300900655 endingPage "1391" @default.
• W4300900655 startingPage "1387" @default.
• W4300900655 abstract "No AccessJournal of UrologyClinical Urology: Original Articles1 Oct 1998LIMITED ROLE OF RADIONUCLIDE BONE SCINTIGRAPHY IN PATIENTS WITH PROSTATE SPECIFIC ANTIGEN ELEVATIONS AFTER RADICAL PROSTATECTOMY MICHAEL L. CHER, FERNANDO J. BIANCO, JOHN S. LAM, LAWRENCE P. DAVIS, DAVID J. GRIGNON, WAEL A. SAKR, MOUSUMI BANERJEE, J. EDSON PONTES, and DAVID P. WOOD MICHAEL L. CHERMICHAEL L. CHER More articles by this author , FERNANDO J. BIANCOFERNANDO J. BIANCO More articles by this author , JOHN S. LAMJOHN S. LAM More articles by this author , LAWRENCE P. DAVISLAWRENCE P. DAVIS More articles by this author , DAVID J. GRIGNONDAVID J. GRIGNON More articles by this author , WAEL A. SAKRWAEL A. SAKR More articles by this author , MOUSUMI BANERJEEMOUSUMI BANERJEE More articles by this author , J. EDSON PONTESJ. EDSON PONTES More articles by this author , and DAVID P. WOODDAVID P. WOOD More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)62545-XAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Bone scintigrams of patients with increasing serum prostate specific antigen (PSA) after radical prostatectomy are only rarely positive. We identify clinical parameters that would improve our ability to select patients for this imaging study. Materials and Methods: We reviewed all bone scintigrams done at our institution between 1991 and 1996 in patients with persistently increasing serum PSA after radical prostatectomy. What prompted the clinician to obtain the bone scintigram was trigger PSA (tPSA). The rate of increase in PSA to tPSA was measured by tPSA/time from radical prostatectomy (slope 1) and tPSA/time from last undetectable PSA (slope 2). These parameters were evaluated together with standard clinicopathological data in univariate and multivariate analyses to determine the ability to predict the bone scintigram result. Results: In univariate analysis tPSA (p = 0.003), slope 1 (p = 0.005) and slope 2 (p = 0.004) were useful in predicting the bone scintigram result but pathological stage, Gleason score, preoperative PSA and time to recurrence were not. In multivariate analysis the single most useful parameter in predicting the bone scintigram result was tPSA (p = 0.01). Based on a logistic regression model the probability of a positive bone scintigram was less than 5% until tPSA increased to 40 to 45 ng./ml. Conclusions: In patients with increasing serum PSA after radical prostatectomy current serum PSA is the best predictor of the bone scintigram result. Furthermore, there is limited usefulness of bone scintigraphy until PSA increases above 30 to 40 ng./ml. References 1 : Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol. Clin. N. Amer.1997; 24: 395. Google Scholar 2 : Evaluating the radical prostatectomy specimen. I: A protocol for establishing prognostic parameters and harvesting fresh tissue samples. J. Urol. Path.1995; 3-4: 377. Google Scholar 3 : Staging and reporting of prostate cancer-sampling of the radical prostatectomy specimen. Cancer1996; 78: 366. Google Scholar 4 : Accuracy of 99mTC-diphosphonate bone scans and roentgenograms in the detection of prostate, breast and lung carcinoma metastases. AJR, Radium Ther. Nucl. Med.1975; 125: 972. Google Scholar 5 : Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology1976; 121: 431. Google Scholar 6 : The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. J.A.M.A.1993; 269: 57. Google Scholar 7 : Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol. Clin. N. Amer.1997; 24: 389. Google Scholar 8 : Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J. Urol.1991; 145: 313. Link, Google Scholar 9 : Patient evaluation if prostate-specific antigen becomes elevated following radical prostatectomy or radiation therapy. Urol. Clin. N. Amer.1994; 21: 677. Google Scholar 10 : Clinical use of prostate specific antigen in patients with prostate cancer. J. Urol.1989; 142: 1011. Link, Google Scholar 11 : The value of serum prostate specific antigen determinations before and after radical prostatectomy. J. Urol.1989; 141: 873. Link, Google Scholar 12 : Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. Brit. J. Urol.1992; 70: 295. Google Scholar 13 : Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J. Nucl. Med.1991; 32: 1713. Google Scholar 14 : Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology1994; 43: 649. Google Scholar 15 : The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J. Urol.1995; 154: 2128. Link, Google Scholar 16 : Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy. J. Urol.1989; 142: 1082. Link, Google Scholar 17 : Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer. Clin. Nucl. Med.1996; 21: 759. Google Scholar 18 : Imaging prostate cancer with technetium-99m-7E11-C5.3 (CYT-351). J. Nucl. Med.1997; 38: 675. Google Scholar 19 : Presence of circulating prostate cells in the bone-marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J. Clin. Oncol.1997; 15: 3451. Google Scholar From the Departments of Urology, Radiology and Pathology, Wayne State University School of Medicine and Program in Genitourinary Oncology, Karmanos Cancer Institute, Detroit, Michigan© 1998 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byRobertson N, Sala E, Benz M, Landa J, Scardino P, Scher H, Hricak H and Vargas H (2018) Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical ProstatectomyJournal of Urology, VOL. 198, NO. 1, (65-70), Online publication date: 1-Jul-2017.Giovacchini G, Picchio M, Briganti A, Cozzarini C, Scattoni V, Salonia A, Landoni C, Gianolli L, Di Muzio N, Rigatti P, Montorsi F and Messa C (2018) [11C]Choline Positron Emission Tomography/Computerized Tomography to Restage Prostate Cancer Cases With Biochemical Failure After Radical Prostatectomy and No Disease Evidence on Conventional ImagingJournal of Urology, VOL. 184, NO. 3, (938-943), Online publication date: 1-Sep-2010.Choueiri T, Dreicer R, Paciorek A, Carroll P and Konety B (2018) A Model That Predicts the Probability of Positive Imaging in Prostate Cancer Cases With Biochemical Failure After Initial Definitive Local TherapyJournal of Urology, VOL. 179, NO. 3, (906-910), Online publication date: 1-Mar-2008.Sandler H and Eisenberger M (2007) Assessing and Treating Patients With Increasing Prostate Specific Antigen Following Radical ProstatectomyJournal of Urology, VOL. 178, NO. 3S, (S20-S24), Online publication date: 1-Sep-2007.OKOTIE O, ARONSON W, WIEDER J, LIAO Y, DOREY F, deKERNION J and FREEDLAND S (2018) PREDICTORS OF METASTATIC DISEASE IN MEN WITH BIOCHEMICAL FAILURE FOLLOWING RADICAL PROSTATECTOMYJournal of Urology, VOL. 171, NO. 6 Part 1, (2260-2264), Online publication date: 1-Jun-2004.WILKINSON S and CHODAK G (2018) THE ROLE OF 111INDIUM-CAPROMAB PENDETIDE IMAGING FOR ASSESSING BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMYJournal of Urology, VOL. 172, NO. 1, (133-136), Online publication date: 1-Jul-2004.MOUL J (2018) PROSTATE SPECIFIC ANTIGEN ONLY PROGRESSION OF PROSTATE CANCERJournal of Urology, VOL. 163, NO. 6, (1632-1642), Online publication date: 1-Jun-2000. Volume 160Issue 4October 1998Page: 1387-1391 Advertisement Copyright & Permissions© 1998 by American Urological Association, Inc.MetricsAuthor Information MICHAEL L. CHER More articles by this author FERNANDO J. BIANCO More articles by this author JOHN S. LAM More articles by this author LAWRENCE P. DAVIS More articles by this author DAVID J. GRIGNON More articles by this author WAEL A. SAKR More articles by this author MOUSUMI BANERJEE More articles by this author J. EDSON PONTES More articles by this author DAVID P. WOOD More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W4300900655 created "2022-10-04" @default.
• W4300900655 creator A5002142016 @default.
• W4300900655 creator A5012197303 @default.
• W4300900655 creator A5014281092 @default.
• W4300900655 creator A5027009066 @default.
• W4300900655 creator A5027252312 @default.
• W4300900655 creator A5034852534 @default.
• W4300900655 creator A5036375446 @default.
• W4300900655 creator A5054445751 @default.
• W4300900655 creator A5063054125 @default.
• W4300900655 date "1998-10-01" @default.
• W4300900655 modified "2023-10-01" @default.
• W4300900655 title "LIMITED ROLE OF RADIONUCLIDE BONE SCINTIGRAPHY IN PATIENTS WITH PROSTATE SPECIFIC ANTIGEN ELEVATIONS AFTER RADICAL PROSTATECTOMY" @default.
• W4300900655 cites W1258323304 @default.
• W4300900655 cites W1717462707 @default.
• W4300900655 cites W1967770117 @default.
• W4300900655 cites W1983118050 @default.
• W4300900655 cites W1985408234 @default.
• W4300900655 cites W2004195861 @default.
• W4300900655 cites W2030753560 @default.
• W4300900655 cites W2047784025 @default.
• W4300900655 cites W2075948860 @default.
• W4300900655 cites W2092686639 @default.
• W4300900655 cites W2167774565 @default.
• W4300900655 cites W2401434096 @default.
• W4300900655 cites W4240477287 @default.
• W4300900655 cites W42639213 @default.
• W4300900655 cites W69788875 @default.
• W4300900655 cites W96058809 @default.
• W4300900655 doi "https://doi.org/10.1016/s0022-5347(01)62545-x" @default.
• W4300900655 hasPublicationYear "1998" @default.
• W4300900655 type Work @default.
• W4300900655 citedByCount "154" @default.
• W4300900655 countsByYear W43009006552012 @default.
• W4300900655 countsByYear W43009006552013 @default.
• W4300900655 countsByYear W43009006552014 @default.
• W4300900655 countsByYear W43009006552015 @default.
• W4300900655 countsByYear W43009006552016 @default.
• W4300900655 countsByYear W43009006552017 @default.
• W4300900655 countsByYear W43009006552018 @default.
• W4300900655 countsByYear W43009006552019 @default.
• W4300900655 countsByYear W43009006552020 @default.
• W4300900655 countsByYear W43009006552021 @default.
• W4300900655 countsByYear W43009006552023 @default.
• W4300900655 crossrefType "journal-article" @default.
• W4300900655 hasAuthorship W4300900655A5002142016 @default.
• W4300900655 hasAuthorship W4300900655A5012197303 @default.
• W4300900655 hasAuthorship W4300900655A5014281092 @default.
• W4300900655 hasAuthorship W4300900655A5027009066 @default.
• W4300900655 hasAuthorship W4300900655A5027252312 @default.
• W4300900655 hasAuthorship W4300900655A5034852534 @default.
• W4300900655 hasAuthorship W4300900655A5036375446 @default.
• W4300900655 hasAuthorship W4300900655A5054445751 @default.
• W4300900655 hasAuthorship W4300900655A5063054125 @default.
• W4300900655 hasConcept C121332964 @default.
• W4300900655 hasConcept C121608353 @default.
• W4300900655 hasConcept C126322002 @default.
• W4300900655 hasConcept C126894567 @default.
• W4300900655 hasConcept C158973077 @default.
• W4300900655 hasConcept C2776049877 @default.
• W4300900655 hasConcept C2776235491 @default.
• W4300900655 hasConcept C2779466945 @default.
• W4300900655 hasConcept C2779902710 @default.
• W4300900655 hasConcept C2780192828 @default.
• W4300900655 hasConcept C2781406297 @default.
• W4300900655 hasConcept C2989005 @default.
• W4300900655 hasConcept C2992596254 @default.
• W4300900655 hasConcept C522557706 @default.
• W4300900655 hasConcept C62520636 @default.
• W4300900655 hasConcept C71924100 @default.
• W4300900655 hasConceptScore W4300900655C121332964 @default.
• W4300900655 hasConceptScore W4300900655C121608353 @default.
• W4300900655 hasConceptScore W4300900655C126322002 @default.
• W4300900655 hasConceptScore W4300900655C126894567 @default.
• W4300900655 hasConceptScore W4300900655C158973077 @default.
• W4300900655 hasConceptScore W4300900655C2776049877 @default.
• W4300900655 hasConceptScore W4300900655C2776235491 @default.
• W4300900655 hasConceptScore W4300900655C2779466945 @default.
• W4300900655 hasConceptScore W4300900655C2779902710 @default.
• W4300900655 hasConceptScore W4300900655C2780192828 @default.
• W4300900655 hasConceptScore W4300900655C2781406297 @default.
• W4300900655 hasConceptScore W4300900655C2989005 @default.
• W4300900655 hasConceptScore W4300900655C2992596254 @default.
• W4300900655 hasConceptScore W4300900655C522557706 @default.
• W4300900655 hasConceptScore W4300900655C62520636 @default.
• W4300900655 hasConceptScore W4300900655C71924100 @default.
• W4300900655 hasIssue "4" @default.
• W4300900655 hasLocation W43009006551 @default.
• W4300900655 hasOpenAccess W4300900655 @default.
• W4300900655 hasPrimaryLocation W43009006551 @default.
• W4300900655 hasRelatedWork W1967410728 @default.
• W4300900655 hasRelatedWork W1967788236 @default.
• W4300900655 hasRelatedWork W2038565121 @default.
• W4300900655 hasRelatedWork W2081453595 @default.
• W4300900655 hasRelatedWork W2093197441 @default.
• W4300900655 hasRelatedWork W2095061769 @default.
• W4300900655 hasRelatedWork W2897445903 @default.

• next